IP Library Granted Patent US 7,084,115
Granted Patent B2
US 7,084,115 · App. 10/425,569 · Granted Aug 1, 2006

Inositol pyrophosphates, and methods of use thereof

Assignee: OxyPlus, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,084,115
App. No.
10/425,569
Granted
Aug 1, 2006
Kind
B2
Abstract

The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells.

Claims (14)

1. A composition, comprising a salt complex comprising an aliphatic ammonium cation, and an anionic ligand for an allosteric site of hemoglobin, wherein the anionic ligand comprises an internal pyrophosphate ring.

2. The composition of claim 1 , wherein the anionic ligand comprises two internal pyrophosphate rings.

3. The composition of claim 2 , wherein the anionic ligand comprises three internal pyrophosphate rings.

4. The composition of claim 1 , wherein the anionic ligand is a phosphorylated inositol.

5. The composition of claim 1 , wherein the anionic ligand is an inositol hexaphosphate.

6. The composition of claim 1 , wherein the aliphatic ammonium cation is a lipophilic, water-soluble aliphatic ammonium cation.

7. The composition of claim 1 , wherein the aliphatic ammonium cation is a monoalkyl, dialkyl, trialkyl or tetraalkyl ammonium moiety.

8. The composition of claim 1 , wherein the aliphatic ammonium cation is an N,N-dimethylcyclohexylammonium cation.

9. The composition of claim 1 , wherein the aliphatic ammonium cation is a monoalkyl ammonium cation.

10. The composition of claim 1 , wherein the aliphatic ammonium cation is a primary ammonium cation.

11. A pharmaceutical formulation, comprising a composition of claim 1 ; and a pharmaceutically acceptable excipient.

12. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal a therapeutically effective amount of a composition of claim 1 .

13. The method of claim 12 , wherein the composition is administered orally.

14. A method of enhancing oxygen delivery to a tissue or organ of a mammal, comprising the step of administering to a mammal red blood cells previously treated with a composition of claim 1 .

Assignments (6)
NUNC PRO TUNC ASSIGNMENT Recorded May 17, 2010
From: UNIVERSITE DE STRASBOURG
To: NORMOXYS, INC.
Reel/Frame 024393/0459 →
NUNC PRO TUNC ASSIGNMENT Recorded Jan 4, 2010
From: NORMOXYS, INC.
To: NORMOXYS, INC.; UNIVERSITE DE STRASBOURG
Reel/Frame 023729/0458 →
CHANGE OF NAME Recorded Jun 12, 2009
From: OXYPLUS, INC.
To: NORMOXYS, INC.
Reel/Frame 022813/0892 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2005
From: GMP|OXYCELL, INC.
To: OXYPLUS, INC.
Reel/Frame 015542/0323 →
SECURITY AGREEMENT Recorded Sep 16, 2004
From: OXYPLUS, INC.
To: GMP/OXYCELL, INC.
Reel/Frame 015144/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2003
From: NICOLAU, YVES CLAUDE; LEHN, JEAN-MARIE; FYLAKTAKIDOU, KONSTANTINA; GREFERATH, RUTH
To: GMP/OXYCELL, INC.
Reel/Frame 014540/0123 →
Continuity (5)
Provisional Application 6042457300 · Nov 7, 2002
Provisional Application 6039574900 · Jul 12, 2002
Provisional Application 6038885100 · Jun 14, 2002
Provisional Application 6037638300 · Apr 29, 2002
Related Publication 20040014642A1 · Jan 22, 2004